Literature DB >> 25849390

The crystal structure of phosphorylated MAPK13 reveals common structural features and differences in p38 MAPK family activation.

Zeynep Yurtsever1, Suzanne M Scheaffer2, Arthur G Romero2, Michael J Holtzman2, Tom J Brett2.   

Abstract

The p38 MAP kinases (p38 MAPKs) represent an important family centrally involved in mediating extracellular signaling. Recent studies indicate that family members such as MAPK13 (p38δ) display a selective cellular and tissue expression and are therefore involved in specific diseases. Detailed structural studies of all p38 MAPK family members are crucial for the design of specific inhibitors. In order to facilitate such ventures, the structure of MAPK13 was determined in both the inactive (unphosphorylated; MAPK13) and active (dual phosphorylated; MAPK13/pTpY) forms. Here, the first preparation, crystallization and structure determination of MAPK13/pTpY are presented and the structure is compared with the previously reported structure of MAPK13 in order to facilitate studies for structure-based drug design. A comprehensive analysis of inactive versus active structures for the p38 MAPK family is also presented. It is found that MAPK13 undergoes a larger interlobe configurational rearrangement upon activation compared with MAPK14. Surprisingly, the analysis of activated p38 MAPK structures (MAP12/pTpY, MAPK13/pTpY and MAPK14/pTpY) reveals that, despite a high degree of sequence similarity, different side chains are used to coordinate the phosphorylated residues. There are also differences in the rearrangement of the hinge region that occur in MAPK14 compared with MAPK13 which would affect inhibitor binding. A thorough examination of all of the active (phosphorylated) and inactive (unphosphorylated) p38 MAPK family member structures was performed to reveal a common structural basis of activation for the p38 MAP kinase family and to identify structural differences that may be exploited for developing family member-specific inhibitors.

Entities:  

Keywords:  MAPK13; p38 MAP kinases

Mesh:

Substances:

Year:  2015        PMID: 25849390      PMCID: PMC4388263          DOI: 10.1107/S1399004715001212

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  27 in total

1.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model.

Authors:  A A Vaguine; J Richelle; S J Wodak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

2.  Alternative p38 MAPKs are essential for collagen-induced arthritis.

Authors:  Gabriel Criado; Ana Risco; Dayanira Alsina-Beauchamp; María J Pérez-Lorenzo; Alejandra Escós; Ana Cuenda
Journal:  Arthritis Rheumatol       Date:  2014-05       Impact factor: 10.995

3.  Mitogen-activated protein kinase (MAPK) phosphatase 3-mediated cross-talk between MAPKs ERK2 and p38alpha.

Authors:  Yuan-Yuan Zhang; Jia-Wei Wu; Zhi-Xin Wang
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

5.  Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38γ and p38δ, linking inflammation and cancer in colitis-associated colon cancer.

Authors:  Paloma Del Reino; Dayanira Alsina-Beauchamp; Alejandra Escós; Ma Isabel Cerezo-Guisado; Ana Risco; Noelia Aparicio; Rafal Zur; Marian Fernandez-Estévez; Elena Collantes; Jose Montans; Ana Cuenda
Journal:  Cancer Res       Date:  2014-09-12       Impact factor: 12.701

6.  New Insights into the p38γ and p38δ MAPK Pathways.

Authors:  Ana Risco; Ana Cuenda
Journal:  J Signal Transduct       Date:  2011-11-30

7.  Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis.

Authors:  Grzegorz Sumara; Ivan Formentini; Stephan Collins; Izabela Sumara; Renata Windak; Bernd Bodenmiller; Reshma Ramracheya; Dorothée Caille; Huiping Jiang; Kenneth A Platt; Paolo Meda; Rudolf Aebersold; Patrik Rorsman; Romeo Ricci
Journal:  Cell       Date:  2009-01-08       Impact factor: 41.582

8.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04

9.  IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.

Authors:  Yael G Alevy; Anand C Patel; Arthur G Romero; Dhara A Patel; Jennifer Tucker; William T Roswit; Chantel A Miller; Richard F Heier; Derek E Byers; Tom J Brett; Michael J Holtzman
Journal:  J Clin Invest       Date:  2012-11-26       Impact factor: 14.808

10.  BALBES: a molecular-replacement pipeline.

Authors:  Fei Long; Alexei A Vagin; Paul Young; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-12-05
View more
  8 in total

Review 1.  CLCA1 and TMEM16A: the link towards a potential cure for airway diseases.

Authors:  Tom J Brett
Journal:  Expert Rev Respir Med       Date:  2015-08-20       Impact factor: 3.772

2.  The pathogenesis shared between abdominal aortic aneurysms and intracranial aneurysms: a microarray analysis.

Authors:  Wen Wang; Hao Li; Zheng Zhao; Haoyuan Wang; Dong Zhang; Yan Zhang; Qing Lan; Jiangfei Wang; Yong Cao; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2017-10-14       Impact factor: 3.042

3.  First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes.

Authors:  Zeynep Yurtsever; Dhara A Patel; Daniel L Kober; Alvin Su; Chantel A Miller; Arthur G Romero; Michael J Holtzman; Tom J Brett
Journal:  Biochim Biophys Acta       Date:  2016-06-29

Review 4.  A Special View of What Was Almost Forgotten: p38δ MAPK.

Authors:  Débora Bublitz Anton; Rodrigo Gay Ducati; Luís Fernando Saraiva Macedo Timmers; Stefan Laufer; Márcia Inês Goettert
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

5.  Peripheral-blood gene expression profiling studies for coronary artery disease and its severity in Xinjiang population in China.

Authors:  Meng Liu; Shubin Jiang; Yu Ma; Jun Ma; Waseem Hassan; Jing Shang
Journal:  Lipids Health Dis       Date:  2018-07-18       Impact factor: 3.876

6.  p38 MAPK pathway and its interaction with TRF2 in cisplatin induced chemotherapeutic response in head and neck cancer.

Authors:  Shomereeta Roy; Souvick Roy; Madhabananda Kar; Shweta Thakur; Yusuf Akhter; Amit Kumar; Francesco Delogu; Swatishree Padhi; Arka Saha; Birendranath Banerjee
Journal:  Oncogenesis       Date:  2018-07-09       Impact factor: 7.485

7.  Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.

Authors:  Blake E Smith; Stephen L Wang; Saul Jaime-Figueroa; Alicia Harbin; Jing Wang; Brian D Hamman; Craig M Crews
Journal:  Nat Commun       Date:  2019-01-10       Impact factor: 14.919

8.  Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same.

Authors:  Vishal Sahu; Lokesh Nigam; Vertica Agnihotri; Abhishek Gupta; Shashank Shekhar; Naidu Subbarao; Suman Bhaskar; Sharmistha Dey
Journal:  Cancer Res Treat       Date:  2018-05-09       Impact factor: 4.679

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.